Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 2/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.33 |
| ▸ | RELA | Q04206 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23565060 | 0.83 | TSHR (0.37) | ABL1MAPT | |
| SCHEMBL29760520 | 0.83 | TSHR (0.37) | ABL1MAPT | |
| SCHEMBL15156638 | 0.81 | NR1H2 (0.37) | ABL1AAK1IRAK4BRD4PAX8 | |
| SCHEMBL18157855 | 0.81 | ABL1 (0.39) | ABL1AAK1IRAK4BRD4PAX8 | |
| SCHEMBL30369795 | 0.81 | ABL1 (0.39) | ABL1AAK1IRAK4BRD4PAX8 | |
| SCHEMBL22115129 | 0.77 | ABL1 (0.38) | ABL1IRAK4BRD4PAX8MAPT | |
| SCHEMBL23567733 | 0.77 | NPSR1 (0.38) | GAAMAPTMAPK1 | |
| SCHEMBL21815586 | 0.76 | ABL1 (0.36) | ABL1AAK1BRD4PAX8GAA | |
| SCHEMBL23525025 | 0.75 | FSCN1 (0.42) | GAAMAPTMAPK1 | |
| SCHEMBL23525133 | 0.75 | CD44 (0.35) | GAAMAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240132477-A1 | Benzimidazole Derivatives and Their Use As Inhibitors of ITK For The Treatment of Skin Disease | PFIZER INC. (US) | 2024-04-25 | — | — | US | disclosed |
| EP-4263526-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS INHIBITORS OF ITK FOR THE TREATMENT OF SKIN DISEASE | Pfizer Inc. (US) | 2023-10-25 | — | — | EP | disclosed |
| US-20230280220-A1 | Benzimidazole Derivative Compounds and Uses Thereof | PFIZER INC. (US) | 2023-09-07 | — | — | US | disclosed |
| US-20230280220-A1 | Benzimidazole Derivative Compounds and Uses Thereof | PFIZER INC. (US) | 2023-09-07 | — | — | US | disclosed |
| US-20230280220-A1 | Benzimidazole Derivative Compounds and Uses Thereof | PFIZER INC. (US) | 2023-09-07 | — | — | US | disclosed |
| US-11661419-B2 | Benzimidazole derivative compounds and uses thereof | PFIZER INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-11661419-B2 | Benzimidazole derivative compounds and uses thereof | PFIZER INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-11661419-B2 | Benzimidazole derivative compounds and uses thereof | PFIZER INC. (US) | 2023-05-30 | — | — | US | disclosed |
| CN-115087655-A | Benzimidazole derivatives | 辉瑞公司 | 2022-09-20 | — | — | CN | disclosed |
| WO-2022130171-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS INHIBITORS OF ITK FOR THE TREATMENT OF SKIN DISEASE | PFIZER INC. (US) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022130171-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS INHIBITORS OF ITK FOR THE TREATMENT OF SKIN DISEASE | PFIZER INC. (US) | 2022-06-23 | — | — | WO | disclosed |
| US-20210188829-A1 | Chemical Compounds | PFIZER INC. (US) | 2021-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132477-A1 | Benzimidazole Derivatives and Their Use As Inhibitors of ITK For The Treatment of Skin Disease | ITK, BLK, BCKDK | ABL1 96/4885AAK1 465/4885IRAK4 56/4885 |
| US-11661419-B2 | Benzimidazole derivative compounds and uses thereof | ITK, HRH4, BLK | ABL1 61/4885AAK1 521/4885IRAK4 70/4885 |
| US-20210188829-A1 | Chemical Compounds | ITK, HRH4, HRH1 | ABL1 23/4885AAK1 402/4885IRAK4 180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.